through the

Introduction: The increase in life expectancy and the aging of the population are associated with an increase in the prevalence of chronic diseases. Comorbidities have an important impact on prognosis and functional capacity leading to a progressive deterioration of autonomy and quality of life and an increase in demand for medical care. Establishment of an accurate prognosis constitutes one of the primary objectives in healthcare. An accurate estimate of prognosis helps clinicians make diagnostic and therapeutic decisions, prevent iatrogenesis, and consider palliative care strategy as needed. It also allows the patient and family members to organize their preferences and priorities. Objective: To evaluate the PROFUND scale in patients with heart failure from a prognostic point of view. Methods: A multicenter cohort study including patients admitted for heart failure to internal medicine departments over a 6-month period will be carried out. Inclusion criteria are patients with a diagnosis of heart failure and at least two criteria of multipathological patients and NT-proBNP >1500 pg/ml upon admission. The PROFUND scale will be applied to all patients. Patients will be then stratified into four groups according to the PROFUND scale: low, moderate, moderate-high and high mortality risk. Conclusion: Our work is a prospective study that aims to apply the PROFUND scale to patients with heart failure in the hospital setting with the purpose of helping in decision-making with our patients, which could lead to improvements in the management of resources in our health system.

[1]  B. Resnick,et al.  Pain Management in the Post-acute and Long-Term Care Setting: A Clinical Practice Guideline (CPG) from the Society for Post-acute and Long-Term Care Medicine (AMDA). , 2021, Journal of the American Medical Directors Association.

[2]  S. Arora,et al.  Early and Significant Reduction in C-Reactive Protein Levels After Corticosteroid Therapy Is Associated With Reduced Mortality in Patients With COVID-19. , 2021, Journal of hospital medicine.

[3]  C. Campochiaro,et al.  The clinical phenotype of Systemic Sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. , 2021, Rheumatology.

[4]  E. Howell,et al.  Caring for Patients at a COVID-19 Field Hospital. , 2021, Journal of hospital medicine.

[5]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.

[6]  D. Schoenfeld,et al.  Safety Assessment of a Noninvasive Respiratory Protocol for Adults with COVID-19. , 2020, Journal of hospital medicine.

[7]  A. McWilliams,et al.  Insights From Rapid Deployment of a “Virtual Hospital” as Standard Care During the COVID-19 Pandemic , 2020, Annals of Internal Medicine.

[8]  G. Filippatos,et al.  Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes , 2020, Circulation.

[9]  M. Méndez-Bailon,et al.  Clinical Characteristics and Risk Factors for Mortality in Very Old Patients Hospitalized With COVID-19 in Spain , 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.

[10]  G. Filippatos,et al.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.

[11]  O. Wazni,et al.  Clinical Characteristics and Outcomes of Non-ICU Hospitalization for COVID-19 in a Nonepicenter, Centrally Monitored Healthcare System. , 2020, Journal of hospital medicine.

[12]  Leora I. Horwitz,et al.  Trends in COVID-19 Risk-Adjusted Mortality Rates. , 2020, Journal of hospital medicine.

[13]  L. Jacobs,et al.  Physician Workforce Response to the COVID-19 Pandemic at an Academic Medical Center , 2020, Disaster medicine and public health preparedness.

[14]  Richard S. Henry,et al.  Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study , 2020, Journal of Psychosomatic Research.

[15]  B. Thombs,et al.  Assessing differential item functioning for the Social Appearance Anxiety Scale: a Scleroderma Patient-centred Intervention Network (SPIN) Cohort Study , 2020, BMJ Open.

[16]  L. Czirják,et al.  Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database , 2020, Annals of the Rheumatic Diseases.

[17]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[18]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[19]  M. Sim,et al.  Occupational silica exposure in an Australian systemic sclerosis cohort. , 2020, Rheumatology.

[20]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure , 2020, New England Journal of Medicine.

[21]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[22]  D. Furst,et al.  Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. , 2020, Clinical and experimental rheumatology.

[23]  N. Ortego-Centeno,et al.  The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). , 2020, Rheumatology.

[24]  M. Bernabeu-Wittel,et al.  Death risk stratification in elderly patients with covid-19. A comparative cohort study in nursing homes outbreaks , 2020, Archives of Gerontology and Geriatrics.

[25]  Corey Scurlock,et al.  Rapid Implementation and Adaptation of a Telehospitalist Service to Coordinate and Optimize Care for COVID-19 Patients. , 2020, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

[26]  S. Agarwal,et al.  Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19. , 2020, Journal of hospital medicine.

[27]  M. Bernabeu-Wittel,et al.  Effectiveness of a On-Site Medicalization Program for Nursing Homes with COVID-19 Outbreaks , 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.

[28]  J. Ramos-Rincón,et al.  Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry , 2020, Revista Clínica Española (English Edition).

[29]  A. Keniston,et al.  Harnessing the Power of Hospitalists in Operational Disaster Planning: COVID-19 , 2020, Journal of General Internal Medicine.

[30]  J. M. Fernández-Rodríguez,et al.  Medical treatment of type 2 diabetes mellitus: Recommendations of the Diabetes, Obesity and Nutrition Group of the Spanish Society of Internal Medicine. , 2020, Revista clinica espanola.

[31]  M. Inzitari,et al.  Nursing Homes and Long Term Care After COVID-19: A New ERA? , 2020, The journal of nutrition, health & aging.

[32]  T. Brooks,et al.  Pooled Testing for SARS-CoV-2 in Hospitalized Patients. , 2020, Journal of hospital medicine.

[33]  S. Jimenez,et al.  Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. , 2020, Rheumatology.

[34]  A. Evans,et al.  Inpatient Management of COVID-19 Pneumonia: a Practical Approach from the Hospitalist Perspective , 2020, Journal of General Internal Medicine.

[35]  Benji K. Mathews,et al.  Clinical Progress Note: Point-of-Care Ultrasound Applications in COVID-19. , 2020, Journal of hospital medicine.

[36]  W. McDonald,et al.  Altered Mental Status as a Novel Initial Clinical Presentation for COVID-19 Infection in the Elderly , 2020, The American Journal of Geriatric Psychiatry.

[37]  L. Tan,et al.  COVID-19 outbreak in nursing homes in Singapore , 2020, Journal of Microbiology, Immunology and Infection.

[38]  J. Karlawish,et al.  Ethics of reallocating ventilators in the covid-19 pandemic , 2020, BMJ.

[39]  David J. Warne,et al.  Hindsight is 2020 vision: a characterisation of the global response to the COVID-19 pandemic , 2020, BMC Public Health.

[40]  Denise D. Quigley,et al.  COVID‐19 Preparedness in Nursing Homes in the Midst of the Pandemic , 2020, Journal of the American Geriatrics Society.

[41]  T. Mehmood,et al.  Inpatient Care of Patients with COVID-19: A Guide for Hospitalists , 2020, The American Journal of Medicine.

[42]  M. Worm,et al.  Older age onset of systemic sclerosis – accelerated disease progression in all disease subsets , 2020, Rheumatology.

[43]  P. Kaboli,et al.  Perceived Need and Potential Applications of a Telehospitalist Service in Rural Areas. , 2020, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

[44]  R. Harwood,et al.  Atypical presentation of COVID-19 in a frail older person , 2020, Age and ageing.

[45]  D. O’Neill,et al.  COVID-19 in Nursing Homes , 2020, QJM : monthly journal of the Association of Physicians.

[46]  A. G. Rada,et al.  Covid-19: the precarious position of Spain’s nursing homes , 2020, BMJ.

[47]  J. Kirkpatrick,et al.  ASE Statement on Point-of-Care Ultrasound during the 2019 Novel Coronavirus Pandemic , 2020, Journal of the American Society of Echocardiography.

[48]  L. Magnani,et al.  Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum. , 2020, Clinical and experimental rheumatology.

[49]  P. Davidson,et al.  Nursing homes and COVID‐19: We can and should do better , 2020, Journal of clinical nursing.

[50]  P. Kaboli,et al.  Using Telehealth as a Tool for Rural Hospitals in the COVID‐19 Pandemic Response , 2020, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.

[51]  C. Mannelli Whose life to save? Scarce resources allocation in the COVID-19 outbreak , 2020, Journal of Medical Ethics.

[52]  Daniel E Trucil American Geriatrics Society Policy Brief: COVID‐19 and Nursing Homes , 2020, Journal of the American Geriatrics Society.

[53]  Aditi Balakrishna,et al.  Calculated decisions: COVID-19 calculators during extreme resource-limited situations. , 2020, Emergency medicine practice.

[54]  C. Tai,et al.  The Impact of the COVID-19 Pandemic on Disabled and Hospice Home Care Patients , 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.

[55]  WHO must prioritise the needs of older people in its response to the covid-19 pandemic , 2020, BMJ.

[56]  G. Dumyati,et al.  Unprecedented Solutions for Extraordinary Times: Helping Long-Term Care Settings Deal with the COVID-19 Pandemic , 2020, Infection Control & Hospital Epidemiology.

[57]  T. Rea,et al.  Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington , 2020, The New England journal of medicine.

[58]  Lisa Rosenbaum,et al.  Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's Front Line. , 2020, The New England journal of medicine.

[59]  N. Ortego-Centeno,et al.  Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation. , 2020, Autoimmunity reviews.

[60]  Giacomo Grasselli,et al.  Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. , 2020, JAMA.

[61]  M. Hudson,et al.  An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. , 2020, Seminars in arthritis and rheumatism.

[62]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[63]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[64]  R. Gomis,et al.  Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study , 2020, Scientific Reports.

[65]  M. Matucci-Cerinic,et al.  Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. , 2020, Seminars in arthritis and rheumatism.

[66]  N. Ortego-Centeno,et al.  Serodiscordant patients with systemic sclerosis: when antibody does not correspond to skin involvement. , 2020, Clinical and experimental rheumatology.

[67]  Introduction: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[68]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[69]  D. Mikhailidis,et al.  Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box! , 2019, Metabolism: clinical and experimental.

[70]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[71]  A. Levin,et al.  SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. , 2019, The lancet. Diabetes & endocrinology.

[72]  Ami A. Shah,et al.  Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry , 2019, Clinical Rheumatology.

[73]  B. Zinman,et al.  Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. , 2019, Age and ageing.

[74]  B. Thombs,et al.  Factors associated with patient-reported likelihood of using online self-care interventions: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study , 2019, BMJ Open.

[75]  J. McMurray,et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. , 2019, The lancet. Diabetes & endocrinology.

[76]  B. Zinman,et al.  Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. , 2019, JAMA.

[77]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[78]  J. Lovshin,et al.  Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials. , 2019, Canadian journal of diabetes.

[79]  F. Spertini,et al.  Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis , 2019, Arthritis & rheumatology.

[80]  M. Hudson,et al.  Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. , 2019, Rheumatology.

[81]  R. Sauter,et al.  Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis , 2019, Annals of the rheumatic diseases.

[82]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[83]  R. Gómez-Huelgas,et al.  Analysis of hospitalizations by cardiovascular disease in the population with diabetes in Spain , 2019, Revista Clínica Española (English Edition).

[84]  M. Hudson,et al.  Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis , 2019, Annals of the rheumatic diseases.

[85]  C. Denton,et al.  Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort , 2019, Annals of the rheumatic diseases.

[86]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. , 2019, Circulation.

[87]  D. Khanna,et al.  Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features , 2019, RMD Open.

[88]  N. Ortego-Centeno,et al.  Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study , 2019, The Journal of Rheumatology.

[89]  Leslie E. Mueller,et al.  The SHIELD Orange County Project -Multi Drug-Resistant Organism (MDRO) Prevalence in 21 Nursing Homes and Long Term Acute Care Facilities in Southern California. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[90]  U. Müller-Ladner,et al.  Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey , 2019, Arthritis Research & Therapy.

[91]  Charles M. LoPresti,et al.  Point-of-Care Ultrasound for Hospitalists: A Position Statement of the Society of Hospital Medicine. , 2019, Journal of hospital medicine.

[92]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[93]  M. Raji,et al.  Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus , 2019, Therapeutic advances in chronic disease.

[94]  N. Ortego-Centeno,et al.  Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry , 2018, Clinical Rheumatology.

[95]  M. Hudson,et al.  Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality , 2018, Rheumatology.

[96]  M. Mayes,et al.  Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry , 2018, The Journal of Rheumatology.

[97]  V. Steen,et al.  Long‐Term Outcomes in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS) , 2018, Chest.

[98]  Charlie Little,et al.  The Role of Hospital Medicine in Emergency Preparedness: A Framework for Hospitalist Leadership in Disaster Preparedness, Response, and Recovery , 2018, Journal of hospital medicine.

[99]  B. Thombs,et al.  The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts , 2018, Rheumatology.

[100]  J. D. de Vries-Bouwstra,et al.  Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort. , 2018, Clinical and experimental rheumatology.

[101]  N. Ortego-Centeno,et al.  First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study , 2018, Clinical Rheumatology.

[102]  J. Gordon,et al.  Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort , 2018, Pulmonary circulation.

[103]  Flora Kisuule,et al.  Hospital medicine beyond the United States , 2018, International journal of general medicine.

[104]  D. Huscher,et al.  Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group , 2018, Arthritis Research & Therapy.

[105]  R. Guthrie Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[106]  R. Ríos-Fernandez,et al.  Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group , 2018, Rheumatology International.

[107]  D. Furst,et al.  Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center. , 2017, Joint, bone, spine : revue du rhumatisme.

[108]  S. Pocock,et al.  Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department: A Cohort Study , 2017, Annals of internal medicine.

[109]  N. Ortego-Centeno,et al.  Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. , 2017, Seminars in arthritis and rheumatism.

[110]  R. Roussel,et al.  Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‐year patient‐level meta‐analysis of the EDITION clinical studies in people with type 2 diabetes , 2017, Diabetes, obesity & metabolism.

[111]  Neha J. Pagidipati,et al.  Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[112]  N. Ortego-Centeno,et al.  Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. , 2017, Clinical and experimental rheumatology.

[113]  D. Pascual-Figal,et al.  Trends and Characteristics of Hospitalization for Heart Failure in a Population Setting From 2003 to 2013. , 2017, Revista espanola de cardiologia.

[114]  M. Boubaya,et al.  Mapping and predicting mortality from systemic sclerosis , 2017, Annals of the rheumatic diseases.

[115]  S. Griffin,et al.  Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes , 2017, Diabetologia.

[116]  N. Ortego-Centeno,et al.  Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort. , 2017, Autoimmunity reviews.

[117]  B. Zinman,et al.  Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes , 2017, The New England journal of medicine.

[118]  C. Hill,et al.  Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension , 2017, Arthritis Research & Therapy.

[119]  R. Milewski,et al.  The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study , 2017, Rheumatology.

[120]  E. Hachulla,et al.  Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening , 2017, The Journal of Rheumatology.

[121]  Rosa M. Estrada-Y.-Martin,et al.  Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis , 2017, The Journal of Rheumatology.

[122]  K. Khunti,et al.  Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data , 2017, Diabetes, obesity & metabolism.

[123]  N. Ortego-Centeno,et al.  Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). , 2017, Clinical and experimental rheumatology.

[124]  B. Thombs,et al.  Using Optimal Test Assembly Methods for Shortening Patient‐Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale‐6: A Scleroderma Patient‐Centered Intervention Network Cohort Study , 2016, Arthritis care & research.

[125]  M. Hudson,et al.  Anti-HMGCR antibodies in systemic sclerosis , 2016, Medicine.

[126]  K. Dharmarajan Comprehensive Strategies to Reduce Readmissions in Older Patients With Cardiovascular Disease. , 2016, The Canadian journal of cardiology.

[127]  C. Denton,et al.  UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. , 2016, Clinical and experimental rheumatology.

[128]  U. Müller-Ladner,et al.  Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study , 2016, PloS one.

[129]  J. C. Callejas Rubio,et al.  Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. , 2016, Seminars in arthritis and rheumatism.

[130]  S. Proudman,et al.  Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study , 2016, BMC Pulmonary Medicine.

[131]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[132]  R. Wachter,et al.  Zero to 50,000 - The 20th Anniversary of the Hospitalist. , 2016, The New England journal of medicine.

[133]  M. Mayes,et al.  Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations , 2016, Medicine.

[134]  J. Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[135]  M. Hudson,et al.  Relationship Between Disease Characteristics and Oral Radiologic Findings in Systemic Sclerosis: Results From a Canadian Oral Health Study , 2016, Arthritis care & research.

[136]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[137]  M. Hellmich,et al.  Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients , 2016, The Journal of Rheumatology.

[138]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[139]  R. Chang,et al.  Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. , 2015, Seminars in arthritis and rheumatism.

[140]  S. Proudman,et al.  Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis , 2015, Internal medicine journal.

[141]  B. Griffiths,et al.  Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. , 2015, Rheumatology.

[142]  M. Stumvoll,et al.  Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients , 2015, Diabetes, obesity & metabolism.

[143]  D. Furst,et al.  Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis–Related Pulmonary Arterial Hypertension , 2015, Arthritis & rheumatology.

[144]  A. Conde-Martel,et al.  Prevalencia y significado pronóstico de la comorbilidad en la insuficiencia cardiaca , 2015 .

[145]  J. Callejas-Rubio,et al.  Registry of the Spanish Network for Systemic Sclerosis , 2015, Medicine.

[146]  Flora Kisuule,et al.  Hospitalists and Their Impact on Quality, Patient Safety, and Satisfaction. , 2015, Obstetrics and gynecology clinics of North America.

[147]  M. Mayes,et al.  Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects , 2015, Autoimmunity.

[148]  U. Müller-Ladner,et al.  Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database , 2015, Annals of the rheumatic diseases.

[149]  J. Ena,et al.  Hyperglycemia management in patients admitted to internal medicine in Spain: A point-prevalence survey examining adequacy of glycemic control and guideline adherence. , 2015, European journal of internal medicine.

[150]  D. Furst,et al.  Update of EULAR recommendations for the treatment of systemic sclerosis , 2015, Annals of the rheumatic diseases.

[151]  U. Müller-Ladner,et al.  Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. , 2015, Annals of the rheumatic diseases.

[152]  J. Cleland,et al.  The Obesity Paradox in Type 2 Diabetes Mellitus: Relationship of Body Mass Index to Prognosis , 2015, Annals of Internal Medicine.

[153]  M. Humbert,et al.  Validation of two predictive models for survival in pulmonary arterial hypertension , 2015, European Respiratory Journal.

[154]  B. Thombs,et al.  Major Depression Diagnoses Among Patients With Systemic Sclerosis: Baseline and One‐Month Followup , 2015, Arthritis care & research.

[155]  D. M. van der Heijde,et al.  Digital ulcers predict a worse disease course in patients with systemic sclerosis , 2015, Annals of the rheumatic diseases.

[156]  U. Müller-Ladner,et al.  Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population , 2015, Rheumatology.

[157]  F. Formiga,et al.  Comorbidity in heart failure. Results of the Spanish RICA Registry. , 2014, QJM : monthly journal of the Association of Physicians.

[158]  M. Hudson,et al.  Systemic Sclerosis Sine Scleroderma: A Multicenter Study of 1417 Subjects , 2014, The Journal of Rheumatology.

[159]  R. Simms,et al.  Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. , 2014, Clinical and experimental rheumatology.

[160]  M. Hudson,et al.  Prevalence and clinical profiles of 'autoantibody-negative' systemic sclerosis subjects. , 2014, Clinical and experimental rheumatology.

[161]  S. Jimenez,et al.  A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study , 2014, Annals of the rheumatic diseases.

[162]  K. Simpson,et al.  New hospital telemedicine services: potential market for a nighttime telehospitalist service. , 2014, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

[163]  M. Mayes,et al.  Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. , 2014, Seminars in arthritis and rheumatism.

[164]  M. Hudson,et al.  Autoantibodies to the Rpp25 Component of the Th/To Complex are the Most Common Antibodies in Patients with Systemic Sclerosis without Antibodies Detectable by Widely Available Commercial Tests , 2014, The Journal of Rheumatology.

[165]  M. Hudson,et al.  Clinical and Serologic Correlates of Anti‐PM/Scl Antibodies in Systemic Sclerosis: A Multicenter Study of 763 Patients , 2014, Arthritis & rheumatology.

[166]  M. Hudson,et al.  Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort , 2014, Scandinavian journal of rheumatology.

[167]  M. Baron,et al.  Frailty Index to Measure Health Status in People with Systemic Sclerosis , 2014, The Journal of Rheumatology.

[168]  R. Gómez-Huelgas,et al.  Frequency of hypoglycemia and its impact on length of stay, mortality, and short-term readmission in patients with diabetes hospitalized in internal medicine wards. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[169]  F. Formiga,et al.  Basal functional status predicts three-month mortality after a heart failure hospitalization in elderly patients - the prospective RICA study. , 2014, International journal of cardiology.

[170]  D. Huscher,et al.  Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group , 2014, Annals of the rheumatic diseases.

[171]  M. Worm,et al.  Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis , 2014, Annals of the rheumatic diseases.

[172]  D. Khanna,et al.  Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study , 2014, The Journal of Rheumatology.

[173]  P. Boracchi,et al.  Nailfold capillaroscopy in systemic sclerosis: data from the EULAR scleroderma trials and research (EUSTAR) database. , 2013, Microvascular research.

[174]  B. Thombs,et al.  Sleep disturbances in systemic sclerosis: evidence for the role of gastrointestinal symptoms, pain and pruritus. , 2013, Rheumatology.

[175]  U. Müller-Ladner,et al.  Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis , 2013, Annals of the rheumatic diseases.

[176]  M. Hudson,et al.  Systemic Sclerosis in Canada’s North American Native Population: Assessment of Clinical and Serological Manifestations , 2013, The Journal of Rheumatology.

[177]  L. Czirják,et al.  Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study , 2013, Annals of the rheumatic diseases.

[178]  M. Hudson,et al.  Association of Gastroesophageal Factors and Worsening of Forced Vital Capacity in Systemic Sclerosis , 2013, The Journal of Rheumatology.

[179]  Karl Swedberg,et al.  Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.

[180]  A. Tyndall,et al.  Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. , 2013, Rheumatology.

[181]  R. Caporali,et al.  Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. , 2013, Clinical and experimental rheumatology.

[182]  M. Hudson,et al.  Low Socioeconomic Status (Measured by Education) and Outcomes in Systemic Sclerosis: Data from the Canadian Scleroderma Research Group , 2013, The Journal of Rheumatology.

[183]  U. Müller-Ladner,et al.  Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study , 2012, Annals of the rheumatic diseases.

[184]  U. Müller-Ladner,et al.  Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. , 2012, Rheumatology.

[185]  R. Steele,et al.  Longitudinal Study of Renal Function in Systemic Sclerosis , 2012, The Journal of Rheumatology.

[186]  M. Humbert,et al.  TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients , 2012, Annals of the rheumatic diseases.

[187]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[188]  J. Callejas-Rubio,et al.  Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. , 2012, Seminars in arthritis and rheumatism.

[189]  R. Steele,et al.  Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis , 2012, Arthritis care & research.

[190]  Sameer Ather,et al.  Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. , 2012, Journal of the American College of Cardiology.

[191]  R. Steele,et al.  Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis , 2012, Arthritis Research & Therapy.

[192]  B. Levis,et al.  Rates and correlates of sexual activity and impairment among women with systemic sclerosis , 2012, Arthritis care & research.

[193]  M. Mayes,et al.  Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry , 2012, Annals of the rheumatic diseases.

[194]  P. Nash,et al.  Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort , 2011, Arthritis research & therapy.

[195]  B. Thombs,et al.  Measuring Pain in Systemic Sclerosis: Comparison of the Short-form McGill Pain Questionnaire Versus a Single-item Measure of Pain , 2011, The Journal of Rheumatology.

[196]  M. Meurer,et al.  Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features , 2011, Arthritis research & therapy.

[197]  R. Gomis,et al.  Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study , 2011, Diabetologia.

[198]  M. Hudson,et al.  Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[199]  V. Steen,et al.  Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population , 2011, The Journal of Rheumatology.

[200]  R. Steele,et al.  Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis , 2011, The Journal of Rheumatology.

[201]  L. Mouthon,et al.  Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. , 2011, Rheumatology.

[202]  A. Gabrielli,et al.  Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres , 2011, Annals of the rheumatic diseases.

[203]  M. Mayes,et al.  Anti-Fibrillarin Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis , 2011, The Journal of Rheumatology.

[204]  M. Bernabeu-Wittel,et al.  Development of a new predictive model for polypathological patients. The PROFUND index. , 2011, European journal of internal medicine.

[205]  Oliver Distler,et al.  EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research , 2011, Annals of the rheumatic diseases.

[206]  M. Baron,et al.  Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry , 2011, Arthritis care & research.

[207]  M. L. Lopes,et al.  Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group , 2010, Annals of the rheumatic diseases.

[208]  A. Forbes,et al.  Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. , 2010, Rheumatology.

[209]  M. Matucci-Cerinic,et al.  Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database , 2010, The Journal of Rheumatology.

[210]  M. Humbert,et al.  Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.

[211]  E. Feierl,et al.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.

[212]  M. Hudson,et al.  Systemic Sclerosis: Establishing Diagnostic Criteria , 2010, Medicine.

[213]  A. Silman,et al.  Observational Study of Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis , 2010, The Journal of Rheumatology.

[214]  R. Steele,et al.  Malnutrition Is Common in Systemic Sclerosis: Results from the Canadian Scleroderma Research Group Database , 2009, The Journal of Rheumatology.

[215]  R. Steele,et al.  Work Disability in Systemic Sclerosis , 2009, The Journal of Rheumatology.

[216]  T. Therneau,et al.  Hospitalizations after heart failure diagnosis a community perspective. , 2009, Journal of the American College of Cardiology.

[217]  C. Denton,et al.  A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. , 2009, Rheumatology.

[218]  M. Humbert,et al.  The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. , 2009, Arthritis and rheumatism.

[219]  R. Steele,et al.  Clinical Correlates of Self-reported Physical Health Status in Systemic Sclerosis , 2009, The Journal of Rheumatology.

[220]  J. Gerss,et al.  Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors , 2009, The British journal of dermatology.

[221]  W. Lehmacher,et al.  High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy , 2009, Arthritis research & therapy.

[222]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[223]  M. Hudson,et al.  The cost of systemic sclerosis. , 2008, Arthritis and rheumatism.

[224]  W. Lehmacher,et al.  Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. , 2008, Rheumatology.

[225]  M. Hudson,et al.  Reports of abnormal cervical cancer screening tests in systemic sclerosis. , 2008, Rheumatology.

[226]  M. Matucci-Cerinic,et al.  The EULAR Scleroderma Trials And Research group (EUSTAR): an international framework for accelerating scleroderma research , 2008, Current opinion in rheumatology.

[227]  R. Landewé,et al.  European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research , 2008, Annals of the rheumatic diseases.

[228]  M. Humbert,et al.  Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study , 2008, Rheumatology.

[229]  U. Müller-Ladner,et al.  Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database , 2008, Annals of the rheumatic diseases.

[230]  W. Lehmacher,et al.  The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement , 2008, Rheumatology.

[231]  G. Riemekasten,et al.  Management of cutaneous vascular complications in systemic scleroderma: experience from the German network , 2008, Rheumatology International.

[232]  R. Steele,et al.  Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. , 2008, Arthritis and rheumatism.

[233]  M. Aringer,et al.  Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case–control study , 2007, Annals of the rheumatic diseases.

[234]  C. Denton,et al.  Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. , 2007, Rheumatology.

[235]  D. Furst,et al.  The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis , 2007, Annals of the rheumatic diseases.

[236]  U. Müller-Ladner,et al.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.

[237]  P. Emery,et al.  A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.

[238]  M. Humbert,et al.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions , 2006, Annals of the rheumatic diseases.

[239]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[240]  C. Lang,et al.  Non-cardiac comorbidities in chronic heart failure , 2006, Heart.

[241]  M. Humbert,et al.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. , 2005, Arthritis and rheumatism.

[242]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[243]  M. Matucci-Cerinic,et al.  Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group database , 2005, Annals of the rheumatic diseases.

[244]  N. Ramírez-Duque,et al.  Incidencia y características clínicas de los pacientes con pluripatología ingresados en una unidad de medicina interna , 2005 .

[245]  Brenda W Gillespie,et al.  Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. , 2003, Arthritis and rheumatism.

[246]  W. Lim,et al.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study , 2003, Thorax.

[247]  E. Segovia,et al.  Prevalence of heart failure in Asturias (a region in the north of Spain). , 2001, The American journal of cardiology.

[248]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[249]  K. Flaherty,et al.  African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. , 1998, Chest.

[250]  M. Ahern,et al.  A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. , 1995, Australian and New Zealand journal of medicine.

[251]  C. Black Scleroderma—clinical aspects , 1993, Journal of internal medicine.

[252]  T. Medsger,et al.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.

[253]  R. Davidson-Lamb,et al.  Scleroderma , 1977, Anaesthesia.

[254]  A. Feinstein,et al.  The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. , 1974, Journal of chronic diseases.

[255]  A. Blenkinsop World Health , 1957, Royal Society of Health journal.

[256]  C. E. WHO Coronavirus Disease (COVID-19) Dashboard , 2020 .

[257]  A. Singh,et al.  Heart Failure Hospitalization with DPP-4 Inhibitors: A Systematic Review and Meta-analysis of Randomized Controlled Trials , 2019, Indian journal of endocrinology and metabolism.

[258]  B. Thombs,et al.  Physical or Occupational Therapy Utilization in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. , 2019, The Journal of rheumatology.

[259]  W. E. Sanabria,et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. , 2019, Lancet.

[260]  J. Ena,et al.  Derivation and validation model for hospital hypoglycemia. , 2018, European journal of internal medicine.

[261]  D. Furst,et al.  Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. , 2017, Clinical and experimental rheumatology.

[262]  S. Proudman,et al.  Validity of the Workers Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) in patients with systemic sclerosis. , 2017, Clinical and experimental rheumatology.

[263]  C. Viscoli,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[264]  Thomas Hügle,et al.  Late-onset systemic sclerosis--a systematic survey of the EULAR scleroderma trials and research group database. , 2011, Rheumatology.

[265]  M. Baron,et al.  Registries in systemic sclerosis: a worldwide experience. , 2011, Rheumatology.

[266]  S. Schinner Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[267]  J. R. Banegas,et al.  Situación epidemiológica de la insuficiencia cardiaca en España , 2006 .

[268]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.